All Articles

A recent review of liquid biopsy studies found it useful in detecting circulating tumor DNA in patients with early and select advanced non–small cell lung cancer.

A recent review discussed multiple ongoing studies evaluating KRAS G12C inhibitors for the treatment of non–small cell lung cancer harboring the KRAS G12C mutation.

Bispecific antibodies are unique antibody constructs that simultaneously bind 2 antigens, typically targeting an antigen on myeloma cells and a molecule on an immune cell. By using the patient’s immune system to destroy the malignant plasma cells, bispecific antibodies offer a promising treatment to overcome immunosuppression for patients with relapsing/refractory MM (RRMM).⁴

The abstract submission portal is open, and our expert peer-reviewers are standing by, awaiting your evidence-based navigation research studies, quality improvement projects, and best practices to consider for inclusion at the AONN+ Annual Conference.

Little is known about the role of community-based navigation in supportive care delivery for historically marginalized cancer survivors. The purposes of this study were to evaluate supportive care experiences of low-income Black and Latina cancer survivors and examine the care role of their community navigator.

Cancer care is extremely complex, and a truly holistic approach to quality care goes beyond radiation, chemotherapy, and surgery, according to Pamela Goetz, BA, OPN-CG, survivorship program manager at Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital in Washington, DC.

A recent study demonstrates liquid biopsy has high concordance to tissue biopsy in non–small-cell lung cancer, making it an acceptable first-line testing option.

A small study of patients with non–small-cell lung cancer with brain metastasis showed sotorasib had promising efficacy on brain lesions.

A recent retrospective analysis of patients with non–small-cell lung cancer harboring KRAS mutations found immune checkpoint inhibitors have benefit in first- and second-line treatment among KRAS subtypes.